Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 170

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 170
---
 imposes an annual binding shareholders’ “say -on-pay” vote with respect to the compensation of the members of (a) the senior management and (b) the board of directors, (ii) prohibits severance, advances, transaction premiums and similar payments to senior management and directors, and (iii) requires companies to specify various compensation -relatedmatters in their articles of association, thus requiring them to be approved by a shareholders’ vote. Because of the specialized scientific and managerial nature of its business, NLS relies heavily on its ability to attract and retain qualified scientific and technical consultants. In particular, the loss of one or more of its senior management or key consultants could be detrimental to it if NLS cannot recruit suitable replacements in a timely manner. NLS does not currently carry “key person” insurance on the lives of members of senior management. The competition for qualified personnel in the pharmaceutical industry is intense. Due to this intense competition, NLS may be unable to attract and retain qualified personnel necessary for the development of its business or to recruit suitable replacement personnel. NLS may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If NLS is unable to comply, or have not fully complied, with such laws, NLS could face substantial penalties. If NLS obtains FDA approval for any of its product candidates and begin commercializing those products in the United States, its operations may be directly or indirectly through its customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti -KickbackStatute, the federal False Claims Act and physician sunshine laws and regulations. These laws may impact, among other things, its proposed sales, marketing and education programs. In addition, NLS may be subject to patient privacy regulation by both the federal government and the states in which NLS conducts its business. The laws that may affect its ability to operate include: •the federal Anti -KickbackStatute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; •federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare,